QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

22 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-20

Study Completion Date

2024-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

NCT05906732

Long QT Syndrome

TERMINATED PHASE1/PHASE2

QT Variability Pre and Post Cardioversion

NCT00885391

Atrial Fibrillation

COMPLETED

Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients

NCT01745666

Long QT Syndrome Type 1 or 2

UNKNOWN NA

Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients

NCT02241252

Cardiac Arrhythmia Qt Interval, Variation in

COMPLETED NA

Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3

NCT07075445

Long QT Syndrome Type 3 Long QT Syndrome 2

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine if QT interval changes are detected during and after antiarrhythmic drug loading by the designed QT detection algorithm from LINQ ECG.

The QT intervals during the anti arrhythmic loading hospitalization period will be compared for all patients to analyze QT changes that may be caused due to antiarrhythmic drugs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Arrhythmia QT Interval, Variation in Arrhythmias, Cardiac

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LINQ/LINQ II

Algorithm developed and validated to continuously measure QT intervals for every beat using LINQ/LINQ II ECG. This study is aimed at determining if QT interval changes can be detected during antiarrhythmic drug loading by the designed QT detection algorithm from LINQ/LINQ II ECG.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients implanted with LINQ/LINQII prior to the study enrollment (no more than 50% patients implanted with LINQII), but no greater than 2.5 years for LINQ or 3.5 years for LINQII, or patients who are indicated to receive a LINQ/LINQII implant at least 7 days prior to antiarrhythmic drug loading
* Patients who are scheduled to receive antiarrhythmic drug loading
* Age 18-80
* Patient is willing and able to comply with the protocol, including follow-up visits, and performing Holter recordings and patient activation transmissions

Exclusion Criteria

* Patients who have a contraindication to long-term antiarrhythmic therapy
* Patients not suitable for long-term antiarrhythmic therapy
* Patients with a previous, existing cardiac implantation (i.e., cardiac pacemaker or cardiac resynchronization requiring \> 40% pacing, implantable cardioverter defibrillator (ICDs))
* Patients with permanent and persistent AF
* Co-enrollment in another study or planning to participate in a concurrent device study during the course of this clinical study that could confound the results

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No